IBDEI0Q4 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11739,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11739,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,11739,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,11740,0)
 ;;=N03.5^^46^573^16
 ;;^UTILITY(U,$J,358.3,11740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11740,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,11740,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,11740,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,11741,0)
 ;;=N03.6^^46^573^11
 ;;^UTILITY(U,$J,358.3,11741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11741,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,11741,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,11741,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,11742,0)
 ;;=N03.7^^46^573^12
 ;;^UTILITY(U,$J,358.3,11742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11742,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,11742,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,11742,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,11743,0)
 ;;=N03.8^^46^573^19
 ;;^UTILITY(U,$J,358.3,11743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11743,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,11743,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,11743,2)
 ;;=^5015529
 ;;^UTILITY(U,$J,358.3,11744,0)
 ;;=N03.9^^46^573^20
 ;;^UTILITY(U,$J,358.3,11744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11744,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,11744,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,11744,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,11745,0)
 ;;=N04.0^^46^573^59
 ;;^UTILITY(U,$J,358.3,11745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11745,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,11745,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,11745,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,11746,0)
 ;;=N04.1^^46^573^58
 ;;^UTILITY(U,$J,358.3,11746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11746,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,11746,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,11746,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,11747,0)
 ;;=N04.2^^46^573^55
 ;;^UTILITY(U,$J,358.3,11747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11747,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,11747,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,11747,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,11748,0)
 ;;=N04.3^^46^573^56
 ;;^UTILITY(U,$J,358.3,11748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11748,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11748,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,11748,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,11749,0)
 ;;=N04.4^^46^573^54
 ;;^UTILITY(U,$J,358.3,11749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11749,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11749,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,11749,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,11750,0)
 ;;=N04.5^^46^573^57
 ;;^UTILITY(U,$J,358.3,11750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11750,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
